NEWARK, Calif., Feb. 7, 2020 /PRNewswire/ -- Protagonist
Therapeutics, Inc. (Nasdaq:PTGX) today announced that the Company
will present preclinical data on PN-943, the Company's oral,
gut-restricted, alpha-4-beta-7 inhibitor candidate therapeutic, at
the 15th Congress of the European Crohn's and Colitis Organization
(ECCO), which will take place Feb. 12-15,
2020, in Vienna.
Presentation details:
Title: PN-943, an Oral Alpha-4-Beta-7 Integrin Antagonist, Inhibits
MAdCAM1-mediated Proliferation and Cytokine Release from CD4+
T-cells Independent of Trafficking
Location: Messe Wien Exhibition and Congress Center, Hall C -
Poster exhibition
Date: Friday, Feb. 14
Time: 12:30-1:30 p.m. CET
About PN-943
PN-943 is an oral, gut-restricted alpha-4-beta-7 integrin
specific antagonist peptide in clinical development for the
treatment of inflammatory bowel disease. PN-943 is designed to
offer the convenience of oral administration and the potential for
improved safety and tolerability compared to antibody therapeutics
administered by injection that target the alpha-4-beta-7 integrin
pathway. PTG-100, a PN-943 analog, showed evidence of clinical and
histological remission in patients with ulcerative colitis. PN-943
has completed Phase 1 development, demonstrating sustained target
engagement with two weeks of daily administration.
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics is a clinical stage biopharmaceutical
company that utilizes a proprietary technology platform to discover
and develop novel peptide-based drugs to transform existing
treatment paradigms for patients with significant unmet medical
needs. PTG-300 is an injectable hepcidin mimetic in development for
the potential treatment of iron overload anemia and related rare
blood diseases including beta-thalassemia, polycythemia vera and
hereditary hemochromatosis. PTG-200 is an oral, gut-restricted
interleukin-23 receptor specific antagonist peptide in Phase 2
clinical development for the potential treatment of inflammatory
bowel disease, with Crohn's disease as the initial indication. The
Company has a worldwide license and collaboration agreement with
Janssen Biotech, Inc., for the clinical development of PTG-200.
PN-943 is an oral, gut-restricted alpha-4-beta-7 integrin specific
antagonist peptide in clinical development for the potential
treatment of inflammatory bowel disease, with a Phase 2 ulcerative
colitis study expected to commence in the second quarter of
2020.
Protagonist is headquartered in Newark, California. For further information,
please visit http://www.protagonist-inc.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include
statements regarding our intentions or current expectations
concerning, among other things, the potential of PN-943 as a
possible treatment of inflammatory bowel disease, the potential of
improved safety and tolerability for PN-943 compared to antibody
therapeutics administered by injection, the potential for sustained
target engagement with administration of PN-943, the results of
future studies for the treatment of inflammatory bowel disease, the
Company's ability to fund its clinical trials, the initiation of
and enrollment of patients in the Company's clinical trials, the
results of clinical trials and the outlook for our other programs.
In some cases, you can identify these statements by forward-looking
words such as "will," "expect," "potential," or the negative
or plural of these words or similar expressions. Forward-looking
statements are not guarantees of future performance and are subject
to risks and uncertainties that could cause actual results and
events to differ materially from those anticipated, including, but
not limited to, our ability to develop and commercialize our
product candidates, our ability to earn milestone payments under
our collaboration agreement with Janssen, our ability to use and
expand our programs to build a pipeline of product candidates, and
our ability to obtain and maintain regulatory approval of our
product candidates. Additional information concerning these and
other risk factors affecting our business can be found in our
periodic filings with the Securities and Exchange Commission,
including under the heading "Risk Factors" contained in our
Quarterly Report on Form 10-Q for the quarterly period ended
September 30, 2019, filed with the
Securities and Exchange Commission. Forward-looking statements are
not guarantees of future performance, and our actual results of
operations, financial condition and liquidity, and the development
of the industry in which we operate, may differ materially from the
forward-looking statements contained in this press release. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release. We assume no obligation
to update our forward-looking statements, whether as a result of
new information, future events or otherwise, after the date of this
press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-present-preclinical-results-on-pn-943-at-the-15th-congress-of-european-crohns-and-colitis-organization-ecco-300999718.html
SOURCE Protagonist Therapeutics, Inc.